The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Targeting complement to treat PNH and other hematologic diseases
Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, explores the use of complement inhibitors in treating paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated hematologic diseases. FDA-approved complement inhibitors for PNH include eculizumab, ravulizumab, pegcetacoplan, and iptacopan. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Pfizer and Jazz Pharmaceuticals
Honoraria: Alexion, AstraZeneca, Omeros, Sanofi, Sobi
